Systemic medications, particularly selective beta blockers and calcium channel blockers, can significantly influence intraocular pressure (IOP) over time, according to study results published in ...

Taking prescribed beta blockers during hematopoietic stem cell transplantation may increase mortality risk due to suppression ...

India has the highest burden of acute coronary syndrome and ST-elevation myocardial infarction (STEMI). The prevalence of CAD ...

Aims There is a paucity of evidence supporting routine beta blocker (BB) use in patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). The aim of this study ...

Granted permanent U.S. residence, as demonstrated by the issuance of a permanent residence card, i.e., a "Green Card" Granted U.S. citizenship Granted status as a "protected person" under 8 U.S.C.

We assessed whether (1) non-selective beta blocker (NSBB) treatment initiation impacts biomarkers of systemic inflammation and (2) whether these changes in systemic inflammation predict complications ...

Administration of β-blockers may attenuate this pathophysiological response ... blinding of outcome adjudicators, selective outcome reporting and other biases. Two independent reviewers will perform ...

Beta-blockers have traditionally been considered a cornerstone of therapy after acute myocardial infarction (AMI) regardless of left ventricular ejection fraction (LVEF). Beta-blocker use did not ...

Long-term treatment with beta-blockers may not lower the risk of death or myocardial infarction (MI) in patients with MI, a preserved left ventricular ejection fraction (LVEF) of ≥50% and coronary ...

Our findings in a large, population-based registry of over 20 000 patients with a recent hospitalization for documented HF suggest that prescription of a non-selective beta-blocker is associated ...

Beta blockers have been shown to prolong survival in chronic heart failure. It is currently a matter of debate whether any β blocker is superior to the other in terms of improving symptoms, left ...

Puberty blockers were banned indefinitely in the UK for under-18s in December after the Cass Review found there was insufficient evidence to show they were safe. It recommended a clinical trial to ...